Continual Reassessment and Related Dose-Finding Designs
- PMID: 21731191
- PMCID: PMC3128794
- DOI: 10.1214/10-STS332
Continual Reassessment and Related Dose-Finding Designs
Abstract
During the last twenty years there have been considerable methodological developments in the design and analysis of Phase 1, Phase 2 and Phase 1/2 dose-finding studies. Many of these developments are related to the continual reassessment method (CRM), first introduced by O'Quigley, Pepe and Fisher (1990). CRM models have proven themselves to be of practical use and, in this discussion, we investigate the basic approach, some connections to other methods, some generalizations, as well as further applications of the model. We obtain some new results which can provide guidance in practice.
Figures
References
-
- Babb J, Rogatko A, Zacks S. Cancer Phase I clinical trials: Efficient dose escalation with overdose control. Statist Med. 1998;17:1103–1120. - PubMed
-
- Braun T. The bivariate-continual reassessment method. Extending the CRM to phase I trials of two competing outcomes. Controlled Clinical Trials. 2002;23:240–256. - PubMed
-
- Cheung Y-K. On the use of nonparametric curves in phase I trials with low toxicity tolerance. Biometrics. 2002;58:237–240. - PubMed
-
- Cheung Y-K. Coherence principles in dose-finding studies. Biometrika. 2005;92:863–873.
-
- Cheung Y-K, Chappell R. A simple technique to evaluate model sensitivity in the continual reassessment method. Biometrics. 2002;58:671–674. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources